| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | 10 | 10 | 10 | 10 | 10 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,390 | -7,350 | -6,610 | -5,660 | -4,990 |
| Net Income Growth | +67.48% | -11.20% | -16.78% | -13.43% | +44.62% |
Carbylan Therap Cmn (CBYL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Carbylan Therapeutics, Inc. is a specialty pharmaceutical company which focused on the development and commercialization of combination therapies that address unmet medical needs. The Company's product candidate consists of Hydros-TA, which is in clinical trial to treat pain associated with osteoarthritis of the knee. Carbylan Therapeutics, Inc. is headquartered in Palo Alto, California.